Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level

NCT01678313 is registered in ClinicalTrials.gov with Buddhist Tzu Chi General Hospital as lead sponsor.

NCT NCT01678313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01678313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level
Lead sponsor
Buddhist Tzu Chi General Hospital
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
August 31, 2013
Enrollment
140 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia